Evidence map›Paper›PMID 39000555›Full record

ReviewInternational journal of molecular sciences2024

Insight into the Role of the miR-584 Family in Human Cancers.

Mariantonia Braile, Neila Luciano, Davide Carlomagno, Giuliana Salvatore, Francesca Maria Orlandella

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Understanding the Dosage-Dependent Role ofInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mariantonia BraileIRCCS Synlab SDN, 80143 Naples, Italy.
Neila LucianoDipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli "Federico II", 80131 Naples, Italy.ORCID 0000-0002-5239-2910
Davide CarlomagnoDipartimento di Farmacia, Università degli Studi di Napoli "Federico II", 80131 Naples, Italy.
Giuliana SalvatoreCEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy.
Francesca Maria OrlandellaCEINGE-Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy.

Funding

MIUR, PRIN -Bando 2017- grant 2017MHJJ55MUR, Fund for the promotion and policy development of the National Research Program (PNR) DM 737
6 · The paper itself

Abstract

Among the non-coding RNAs, the aberrant expression of microRNAs (miRNAs) is well described in the oncology field. It is clear that the altered expression of miRNAs is crucial for a variety of processes such as proliferation, apoptosis, motility, angiogenesis and metastasis insurgence. Considering these aspects, RNA-based therapies and the use of miRNAs as non-invasive biomarkers for early diagnosis are underlined as promising opportunities against cancer death. In the era of precision medicine, significant progress in next-generation sequencing (NGS) techniques has broadened knowledge regarding the miRNAs expression profile in cancer tissues and in the blood of cancer patients. In this scenario, pre-clinical and clinical studies suggested that the members of the miR-584 family, i.e., miR-584-5p and -3p, are prominent players in cancer development and progression. Under some conditions, these miRNAs are under-expressed in cancer tissues acting as tumor suppressors, while in other conditions, they are overexpressed, acting as oncogenes increasing the aggressive behavior of cancer cells. The aim of this review is to provide a comprehensive and up-to-date overview on the expression, upstream genes, molecular targets and signaling pathways influenced by the miR-584 family (i.e., miR-584-3p and -5p) in various human solid and hematological cancers. To achieve this goal, 64 articles on this topic are discussed. Among these articles, 55 are focused on miR-584-5p, and it is outlined how this miRNA could be used in future applications as a potential new therapeutic strategy and diagnostic tool.

Indexed as

Gene Expression Regulation, NeoplasticMicroRNAsNeoplasmsAnimalsBiomarkers, TumorHumansSignal TransductionBiomarkers, TumorMicroRNAsMIRN574 microRNA, humanbiomarkercancermicroRNAmiR-584target therapy

Identifiers

PMID39000555
PMCPMC11242779

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.